瑞舒伐他汀对血脂正常的高血压患者心踝指数及踝臂指数的影响

Effect of rosuvastatin on cardio-ankle vascular index and ankle-brachial index in essential hypertensives with normal lipidemia

目的观察瑞舒伐他汀对血脂正常的原发性高血压患者心踝指数及踝臂指数的影响。方法不伴高血脂症的原发性高血压患者130例随机分为对照组(n=63)和治疗组(n=67,瑞舒伐他汀10mg,每晚1次),疗程均为3月。入选前所有患者经服用降压药物后血压控制在140/90mmHg以下至少4周。观察心踝血管指数(CAVI)、踝臂指数、血压、血脂在治疗前后的变化。结果治疗3月末时,两组治疗前后及组间血压变化无明显差异。瑞舒伐他汀治疗组治疗3月后总胆固醇、LDL-C较基础值分别降低(1.7±1.0)和(0.7±0.4)mmol/L,与对照组[(-0.10±0.06)、(-0.06±0.03)mmol/L]比较,差异均有统计学意义(均P<0.05)。瑞舒伐他汀组治疗3月后CAVI值降低0.58±0.12,踝臂指数值升高0.18±0.10,与对照组(0.12±0.10、-0.06±0.04)比较,差异均有统计学意义(均P<0.05)。对照组治疗前后血脂各项指标、CAVI及踝臂指数的差异均无统计学意义(P>0.05)。Pearson相关分析及多元逐步回归分析显示,CAVI与年龄、收缩压、总胆固醇、LDL-C呈正相关;踝臂指数与年龄、收缩压、总胆固醇、LDL-C呈负相关(均P<0.05)。结论瑞舒伐他汀可改善血脂正常的原发性高血压患者的动脉弹性功能。

Objective To investigate the effect of rosuvastatin on cardio-ankle vascular index and ankle-brachial index in essential hypertensives with normal lipidemia. Methods One hundred and thirty essential hypertensives with normal lipidemia were divided into two groups： control group（n= 63）and rosuvastatin group （n=67, rosuvastatin 10 mg, qn）. Blood pressure of all the hypertensives were controled under 140/90 mm Hg at least four weeks through given routine antihypertensive drugs. Cardio-ankle vascular index （CAVI） , ankle-hrachial index （ ABI）, blood pressure and lipidemia were measured before and three months after treatment respectively. Results By the end of three months therapy, no significant difference in blood pressure was observed between two groups. Total cholesterol （TC） and low density lipoprotein-cholesterol （LDL-C） were significantly decreased in rosuvastatin group compared with control group [（-0.10±0.06）, （-0.064.0.03） mmol/L] （P〈0.05） and hasline [（1.7±1.0）, （0.7±0.4） mmol/L] {P〈0.05）. CAVI{0. 584-0.12） was significantly decreased in rosuvastatin group compared with control group 10. 12±0. 10）（P〈0. 05）, ABI（0. 184.0.10） was significantly increased in rosuvastatin group compared with control group （ -0.06 ±0.04） （P〈0.05）. There were no significant difference in the lipidemia, CAVI and ABI after three months therapy as compared with baseline （P〉0.05）. CAVI was positively related with age, systolic pressure, TC and LDL-C; ABI was negatively related with age, systolic pressure, TC and LDL-C in Pearson and multiple stepwise regression analysis. Conclusion Rosuvastatin can exert beneficial effect on arterial function in essential hypertensives with normal lipidemia.